Copper-piceatannol nanoparticles as well as preparation method and application thereof

By preparing copper-tamarind nanoparticles that mimic enzyme activity and self-degradation mechanisms, the problems of polyamine regulation and nanomaterial retention in tumor cells were solved, achieving enhanced pyroptosis and immune activation in tumor cells, resulting in highly effective antitumor effects and good biosafety.

CN118903466APending Publication Date: 2024-11-08SHANDONG UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411034134.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing anti-tumor drugs are unable to effectively reduce the level of polyamines in tumor cells, leading to immune evasion and tumor growth. Furthermore, traditional nanomaterials pose safety risks due to long-term retention in the body.

Method used

Copper-tamarind nanoparticles were prepared to mimic the catalytic activity of various enzymes to generate O2 and ·OH from H2O2, consume GSH and polyamines, promote palmitoylation of GSDMD and GSDMD-N by regulating the expression of zDHHC5 and zDHHC9, induce enhanced pyroptosis, and self-degrade in the tumor microenvironment.

Benefits of technology

Copper-taperitone nanoparticles effectively improve hypoxia in the tumor microenvironment, generate ROS, lead to polyamine depletion, enhance pyroptosis, activate anti-tumor immune responses, and rapidly degrade in vivo, reducing toxicity to normal cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903466A_ABST
    Figure CN118903466A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of antitumor drugs, and relates to copper-piceatannol nanoparticles as well as a preparation method and application thereof. The preparation method of the copper-piceatannol nano-particles comprises the following steps: uniformly mixing polyvinylpyrrolidone and cupric salt, adding piceatannol, adjusting the pH value to be not less than 10, and reacting under a stirring condition to obtain nano-particles, namely the copper-piceatannol nano-particles. The copper-piceatannol nano-particles prepared by the invention can realize comprehensive depletion of polyamine in cells to induce and enhance pyroptosis of cells, so as to treat tumors; meanwhile, the material has a biodegradation function, and the problem that an existing nano material is detained in vivo for a long time is solved; in addition, the method also has more excellent biological safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of anti-tumor drugs and relates to copper-piceatannol nanoparticles and a preparation method and application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] As we all know, the tumor microenvironment is characterized by acidity, hypoxia, high levels of hydrogen peroxide (H2O2) and high expression of glutathione (GSH). This specific environment not only promotes the malignant growth, wanton spread and invasion of tumor cells, but also shapes the characteristics of immunosuppression, affects the normal functioning of the immune system and thus reduces the therapeutic effect. Currently, most materials designed using tumor-specific microenvironments can simulate the activity of peroxidase (POD) to catalyze the high concentration of H2O2 in tumor cells to generate hydroxyl radicals (·OH); simulate the activity of catalase (CAT) to catalyze H2O2 to produce oxygen to improve tumor hypoxia; simulate the activity of glutathione oxidase (GSHOx) to oxidize GSH to oxidized glutathione (GSSG), disrupt the intracellular redox balance, increase the level of oxidative stress, and lead to tumor cell death.

[0004] It is little known that polyamines (including putrescine, spermine, and spermidine) are widely involved in regulating the intracellular redox balance as free radical scavengers that exist in large quantities in tumor cells. In addition, the high expression of polyamines in tumor cells brings many negative effects, such as regulating gene expression, evading immune detection, and promoting malignant proliferation. Therefore, reducing the content of intracellular polyamines by targeting polyamines is an effective anti-tumor treatment. Bu et al. constructed MIL-100 loaded with polyamine oxidase to improve the therapeutic effect of oxidative damage by rapidly consuming intracellular polyamines. However, polyamine metabolism in tumor cells is often dysregulated. Arginase 2 (Arg 2) in tumor cells is often highly expressed, which can catalyze the reaction of arginine to generate a large amount of ornithine and urea. The increase of ornithine further promotes the synthesis of polyamines. More importantly, the abnormal increase in the level of polyamine metabolism in tumor cells is conducive to evading the recognition of immune cells, thereby promoting tumor growth and metastasis. Although clinical drugs such as difluoromethylornithine (DFMO) have been used to inhibit polyamine synthesis and have made certain research progress, the clinical results are still unsatisfactory.

[0005] As a unique programmed death mode, pyroptosis is favored by researchers for cancer immunotherapy. Generally speaking, inflammasomes recruit and activate caspase-1 to cleave GSDMD into GSDMD N-terminus and GSDMD C-terminus. The cleaved GSDMD-N can cause cell membrane rupture and release of immunostimulatory cytokines, thereby causing immunogenic cell death. With the continued exploration of pyroptosis, some researchers have shown that S-palmitoylation of GSDMD can make the complete GSDMD have cell membrane perforation properties similar to those of GSDMD-N, thereby activating the pyroptosis pathway. Palmitoylation of GSDMD and GSDMD-N can be increased by inflammasome activation and upregulation of ROS in mitochondria to induce enhanced pyroptosis. This supplement may be a reliable means to make up for the current shortcomings of pyroptosis. The Caspase-1 / GSDMD pathway combined with S-palmitoylation of GSDMD to jointly induce enhanced pyroptosis has profound research potential. Therefore, it is necessary to provide new drugs that can achieve comprehensive depletion of intracellular polyamines to induce enhanced pyroptosis. Summary of the invention

[0006] As a natural polyphenol, piceatannol has a variety of biological activities, such as protecting the skin from ultraviolet radiation; promoting collagen synthesis; and vasodilation. More importantly, piceatannol is an effective arginase inhibitor that can inhibit the activity of arginase 2 in mitochondria and reduce the synthesis of intracellular polyamines. Metal-phenol nanoplatforms are metal-organic materials constructed by metal ions and natural polyphenols. Although they have a simple structure, they have a variety of excellent properties, such as different enzyme-like activities, thermal stability, and pH-responsive decomposition. More importantly, the physicochemical properties and biological functions of the nanoplatform can be designed by carefully selecting metal ions and phenolic ligands. At present, copper ion overload-mediated cell pyroptosis based on copper-based polyphenol materials is designed for tumor treatment. However, research on the use of metal polyphenol materials for anti-tumor treatment against intracellular polyamine consumption has never been reported. The present invention found in the study that copper ions and piceatannol were made into copper-piceatannol nanoparticles, which simulated CAT and POD activity to generate O2 and ·OH, improve tumor hypoxia conditions, and produce ROS. At the same time, it consumes GSH and intracellular polyamines, increasing the accumulation of ROS. Piceatannol inhibits the synthesis pathway of intracellular polyamines; the relief of hypoxia and mitochondrial dysfunction will weaken the ability of cells to take up polyamines; biodegradable copper-piceatannol nanoparticles cause complete depletion of intracellular polyamines, thereby inducing enhanced cell pyroptosis; not only that, the up-regulation of zDHHC5 and zDHHC9 expression further promotes the palmitoylation of GSDMD and GSDMD-N, and the palmitoylated GSDMD and GSDMD-N further enhance cell pyroptosis. In addition, the present invention also unexpectedly discovered through experiments that copper-piceatannol nanoparticles have lower cytotoxicity to normal cells than the combination of copper ions and piceatannol, that is, copper-piceatannol nanoparticles have higher biosafety.

[0007] Based on the above research results, the present invention is proposed. Specifically, the technical solution provided is as follows:

[0008] In a first aspect, a method for preparing copper-piceatannol nanoparticles is provided, wherein polyvinyl pyrrolidone (PVP) and a divalent copper salt are uniformly mixed, after adding piceatannol, the pH value is adjusted to be not less than 10, and then the mixture is reacted under stirring conditions to obtain the copper-piceatannol nanoparticles.

[0009] The divalent copper salt described in the present invention refers to a compound whose cation is a divalent copper ion, such as copper chloride, copper sulfate, copper nitrate, copper acetate, etc.

[0010] In some embodiments, the polyvinyl pyrrolidone has a viscosity grade of K30 and a molecular weight of 44,000-54,000.

[0011] In some embodiments, the input mass ratio of polyvinyl pyrrolidone to divalent copper salt is 2.5 to 6:1, preferably 2.9 to 3.6:1.

[0012] The molar ratio of the divalent copper salt to piceatannol is 2 to 4:1. Studies have shown that in the above reaction system, the molar ratio of the divalent copper salt to piceatannol affects the morphology of the nanoparticles, and the morphology of the nanoparticles affects their biological activity. In some embodiments, the molar ratio of the divalent copper salt to piceatannol is 1.50 to 3.00:1. Studies have shown that when the molar ratio of the divalent copper salt to piceatannol is 1.50 to 3.00:1, especially 1.50 to 2.50:1 and 1.50 to 2.20:1, the copper-piceatannol nanoparticles can be monodispersed and have a better effect.

[0013] In some embodiments, the pH value is adjusted to 11 to 13. Studies have shown that the performance of the nanoparticles obtained under this condition is better.

[0014] In some embodiments, the reaction time under stirring conditions is 8 to 16 hours.

[0015] In some embodiments, the stirring speed is 600-1000 rpm.

[0016] In some embodiments, centrifugal separation is performed after the reaction, with a rotation speed of 11000-13000 rpm and a centrifugal time of 10-20 min.

[0017] In a second aspect, a copper-piceatannol nanoparticle is obtained by the above preparation method.

[0018] In a third aspect, a pharmaceutical composition comprises the above-mentioned copper-piceatannol nanoparticles and pharmaceutical excipients.

[0019] In some embodiments, the pharmaceutical excipient is a pharmaceutical carrier and / or excipient. The pharmaceutical carrier may be serum protein, physiological saline, buffer solution, etc. The excipient may be a suspending agent, emulsifier, stabilizer, suspending agent, adhesive, filler, preservative, fragrance, etc.

[0020] In a fourth aspect, a use of the copper-piceatannol nanoparticles or pharmaceutical composition described above in the preparation of anti-tumor drugs.

[0021] In some embodiments, the anti-tumor drug has any one of the following effects:

[0022] (1) Catalyze H2O2 to produce oxygen and / or hydroxyl radicals;

[0023] (2) Oxidation of glutathione to oxidized glutathione;

[0024] (3) depletion of intracellular polyamines;

[0025] (4) inducing enhanced cell pyroptosis; and / or, promoting the palmitoylation of GSDMD and GSDMD-N by upregulating the expression of zDHHC5 and zDHHC9, thereby further enhancing cell pyroptosis.

[0026] In some embodiments, the tumor is a breast tumor.

[0027] The copper-piceatannol nanoparticles provided by the present invention can simulate multiple enzyme activities so that the copper-piceatannol nanoparticles can effectively improve the hypoxic microenvironment and generate a large amount of ROS. The prepared copper-piceatannol nanoparticles can achieve intracellular polyamine depletion in an all-round way by reducing polyamine uptake, inhibiting polyamine synthesis and enhancing polyamine consumption, thereby causing intracellular redox imbalance and dysfunction of multiple organelles, and then causing inflammasome recruitment and subsequent cleavage of pyroptosis protein GSDMD to successfully induce cell pyroptosis. In addition, the upregulation of zDHHC5 and zDHHC9 expression further promotes the palmitoylation of GSDMD and GSDMD-N, and the palmitoylated GSDMD and GSDMD-N further enhance cell pyroptosis. The occurrence of enhanced cell pyroptosis leads to the leakage of tumor-associated damage molecular patterns (DAMPs), effectively reversing the tumor immunosuppressive microenvironment and activating the anti-tumor immune response in vivo.

[0028] The beneficial effects of the present invention are:

[0029] The copper-piceatannol nanoparticles prepared by the present invention can not only respond to the tumor-specific microenvironment to simulate multiple enzyme activities, effectively improve the tumor microenvironment and generate a large amount of ROS. The copper-piceatannol nanoparticles can respond to the high concentration of GSH, H2O2 and slightly acidic environment in the tumor microenvironment, self-degrade to release copper ions and piceatannol, and after exerting their effects, they can be biodegraded and excreted from the body by the kidneys, thus overcoming the problem of long-term retention of existing nanomaterials in the body. Compared with the simple combined administration of copper and piceatannol, the copper-piceatannol nanoparticles are less toxic to normal cells and have better biosafety.

[0030] Moreover, copper-piceatannol nanoparticles achieved intracellular polyamine depletion by reducing polyamine uptake, inhibiting polyamine synthesis and enhancing polyamine consumption, thereby successfully inducing cell pyroptosis. The upregulation of zDHHC5 and zDHHC9 expression further promoted the palmitoylation of GSDMD and GSDMD-N, and the palmitoylated GSDMD and GSDMD-N further enhanced cell pyroptosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0032] Figure 1 This is a transmission electron microscope (TEM) photograph of the copper-piceatannol nanoparticles prepared in Example 1.

[0033] Figure 2 This is a TEM image of the copper-piceatannol nanoparticles prepared in Comparative Example 1.

[0034] Figure 3 This is a TEM image of the copper-piceatannol nanoparticles prepared in Comparative Example 2.

[0035] Figure 4 This is a curve diagram of the CAT activity simulated by the copper-piceatannol nanoparticles described in Example 1.

[0036] Figure 5 The graph is a graph showing the POD-mimicking activity of the copper-piceatannol nanoparticles described in Example 1 detected using 3,3',5,5'-tetramethylbenzidine (TMB).

[0037] Figure 6 This is a curve diagram showing the GSHOx activity simulated by the copper-piceatannol nanoparticles described in Example 1.

[0038] Figure 7 These are experimental diagrams showing the consumption of spermine (a) and spermidine (b) by copper-piceatannol nanoparticles described in Example 1.

[0039] Figure 8 This is a fluorescence microscopy image of the changes in intracellular O2 after treatment with the copper-piceatannol nanoparticles described in Example 1 detected using the RDPP probe.

[0040] Fig. 9 Fluorescence microscopy images of ROS generation in 4T1 cells treated with copper-piceatannol nanoparticles described in Example 1 detected using a DCFH-DA probe.

[0041] Fig.10 This is a graph showing the experimental consumption of GSH by copper-piceatannol nanoparticles in 4T1 cells as described in Example 1.

[0042] Fig.11 This is an experimental diagram of the consumption of intracellular polyamines by copper-piceatannol nanoparticles in 4T1 cells as described in Example 1.

[0043] Fig.12 This is a diagram of the cytotoxicity experiment of copper-piceatannol nanoparticles described in Example 1.

[0044] Fig.13 This is an experimental diagram of the morphological changes of 4T1 cells induced by copper-piceatannol nanoparticles described in Example 1.

[0045] Fig.14 This is a comparison diagram of the experimental changes in 3T3 cell morphology induced by the copper-piceatannol nanoparticles and the combination of copper and piceatannol described in Example 1.

[0046] Fig.15 This is a comparison chart of the cytotoxicity comparison experiment of the copper-piceatannol nanoparticles and the combined administration of copper ions and piceatannol described in Example 1.

[0047] Fig.16 TEM images of the copper-piceatannol nanoparticles described in Example 1 in response to degradation in acidic pH, H2O2 and GSH. DETAILED DESCRIPTION

[0048] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in combination with specific embodiments and comparative examples.

[0049] Example 1

[0050] The preparation method of biodegradable copper-piceatannol nanoparticles comprises the following steps: 1) weighing 250 mg PVP k30 and mixing it with 10 mL water, and dissolving it by ultrasonication.

[0051] 2) Weigh 85 mg CuCl2·2H2O and mix with 30 mL water and dissolve by ultrasonication.

[0052] 3) Mix the PVP k30 aqueous solution and the CuCl2·2H2O aqueous solution under stirring at 800 rpm and stir for 60 min;

[0053] 4) Slowly add 1 mL of piceatannol methanol solution (60 mg / mL) into the solution.

[0054] 5) The solution was then adjusted to a pH of 12 using sodium hydroxide solution.

[0055] 6) After stirring at room temperature for 12 h, a dark brown solid product was obtained by centrifugation at 12000 rpm for 20 min. In this embodiment, the molar ratio of divalent copper ion to piceatannol was 2:1.

[0056] The copper-piceatannol nanoparticles prepared in Example 1 were characterized by transmission electron microscopy. Figure 1 As shown, it can be seen from the figure that the prepared copper-piceatannol is obviously monodispersed nanoparticles.

[0057] The copper-piceatannol nanoparticles obtained in Example 1 simulated the activities of CAT, POD and GSHOX:

[0058] 1) CAT activity test of simulated copper-piceatannol:

[0059] The CAT activity of copper-piceatannol was characterized by detecting the oxygen concentration produced in the solution. Copper-piceatannol and different concentrations of H2O2 were added to 10 mL PBS (pH = 7.4), and the oxygen concentration displayed on the dissolved oxygen meter was recorded every 30 seconds and continuously monitored for 20 minutes.

[0060] 2) POD activity test of simulated copper-piceatannol:

[0061] Using TMB (3,3',5,5'-tetramethylbiphenyl) as a substrate, different concentrations of copper-piceatannol were dispersed in PBS (pH=5.5), H2O2 was added, and after reacting for 5 minutes, the absorbance at 652 nm was detected using a UV spectrophotometer.

[0062] 3) Simulation of GSHOx activity test:

[0063] DTNB was used as a substrate to detect the GSHOx activity of copper-piceatannol. Different concentrations of copper-piceatannol were dispersed in 2 mL PBS (pH = 7.4), and 50 μL GSH (1 mg mL -1 ), and after 10 minutes of reaction, 50 μL of DTNB (1.5 mg mL -1 ). The absorbance change at 415 nm was recorded using a UV spectrophotometer.

[0064] 4) Oxidative consumption of spermine / spermidine.

[0065] Different concentrations of copper-piceatannol, 100 μL 3% H2O2 and different concentrations of spermine or spermidine were incubated at room temperature for 30 minutes, and the concentration of spermine / spermidine in the supernatant was quantified by gas chromatography-mass spectrometry.

[0066] The above experiments yielded the production of oxygen, ·OH, the consumption of glutathione (GSH), and spermine and spermidine, see Figure 4 , Figure 5 , Figure 6 and Figure 7 .

[0067] Figure 4 In the reaction, H2O2 is the substrate for copper-piceatannol to produce O2, and its concentration seriously affects the generation rate and yield of O2. The higher the concentration of H2O2, the faster the rate of copper-piceatannol to produce oxygen and the higher the yield.

[0068] Figure 5 In the experiment, as the concentration of copper-piceatannol increases, the ability to generate hydroxyl radicals becomes stronger and the absorption peak at 652nm becomes higher.

[0069] Figure 6 In the experiment, as the concentration of copper-piceatannol increases, the ability to consume GSH becomes stronger, the amount of GSH remaining after the reaction becomes less, and the absorption peak becomes lower.

[0070] Figure 7 In the reaction, as the concentration of copper-piceatannol increases, the ability to consume spermine and spermidine becomes stronger, and the remaining amount of spermine and spermidine after the reaction becomes less.

[0071] Intracellular related experiments were carried out, and the experimental process is as follows:

[0072] 5) Intracellular oxygen content detection:

[0073] 4T1 cells were seeded in 6-well plates at 1 × 10 cells per well. 5 The cells were incubated at a density of 24 h and treated with [Ru(dpp)3] 2+ Cl2 (final concentration of 30 μM) was treated for different time periods. Fresh culture medium containing the material was then added to the culture dish and incubated for a period of time, and the red fluorescence image was observed using a fluorescence microscope.

[0074] 6) Detection of intracellular ROS content:

[0075] 4T1 cells were seeded on 6-well plates and cultured for 24 h until the number of cells per well reached 1 × 10 5 After 8 hours of treatment with (a) control and (b) Cu-Pic, the culture medium containing the materials was removed and washed three times with PBS solution. Subsequently, fresh culture medium containing 2′,7′-dichlorofluorescein diacetate (DCFH-DA) was added to each well, and the mixture was incubated at 37°C for 30 minutes. Finally, the green fluorescence image was observed by fluorescence microscopy.

[0076] 7) Detection of intracellular GSH content:

[0077] 4T1 cells were seeded on 6-well plates and cultured for 24 h until the number of cells per well reached 1 × 10 5 The cells were treated with (a) control and (b) Cu-Pic for 8 hours. The GSH detection kit was used to detect the intracellular GSH content.

[0078] 8) Detection of intracellular polyamines

[0079] 4T1 cells were seeded in 6-well plates and cultured for 24 h until the number of cells per well reached 1 × 10 5The cells were treated with (a) control and (b) Cu-Pic for 8 hours. The polyamine content in the cells was detected using a polyamine detection kit.

[0080] Figure 8 The middle red fluorescence gradually weakened over time, indicating that the oxygen concentration gradually increased; Fig. 9 Copper-piceatannol can generate ROS. Compared with the case without adding materials, the green fluorescence is enhanced after adding copper-piceatannol, indicating the generation of ROS. Fig.10 Copper-piceatannol can deplete glutathione in cells. Fig.11 Copper-piceatannol can consume intracellular polyamines. Cell experiments have verified that copper-piceatannol can produce a large amount of ROS and completely consume intracellular polyamines.

[0081] 9) Cytotoxicity assay:

[0082] 4T1 was seeded in a 96-well plate and incubated for 24 h. The cell number was measured by a cell counter and reached 8000 cells per well. Then, different concentrations (0, 6.25, 12.5, 25, 50, and 100 μg mL -1 ) were incubated with copper-piceatannol. After 12 hours, MTT was added to detect cytotoxicity and the absorbance at 490 nm was measured.

[0083] By cytotoxicity test ( Fig.12 ) demonstrated that copper-piceatannol nanoparticles can significantly kill tumor cells.

[0084] 10) Observe cell morphology:

[0085] 4T1 cells were seeded into 6-well plates and incubated for 24 h to allow the cell number to reach 1 × 10 5 Then, the cells were incubated with medium containing different concentrations of copper-piceatannol for 8 hours. The cell morphology was further observed using a fluorescence microscope.

[0086] By observing the cell morphology, it was proved that the nanomaterial can cause 4T1 cells to swell and rupture, and cause cell pyroptosis. Fig.13 As shown, the phenomenon of cell pyroptosis is cell swelling and cell membrane rupture, which is because copper-piceatannol causes complete depletion of intracellular polyamines and upregulates palmitoylated GSDMD and GSDMD-N, thereby inducing enhanced cell pyroptosis.

[0087] 3T3 cells were seeded into 6-well plates and incubated for 24 h to allow the cell number to reach 1 × 10 5 , respectively, with copper-piceatannol nanoparticles (50 μg mL -1 ) were incubated with corresponding amounts of copper ions and piceatannol for 8 hours. The morphology of the cells was further observed using a fluorescence microscope.

[0088] like Fig.14 As shown, by observing the cell morphology, it was proved that copper-leucopterin nanoparticles had no obvious effect on normal cells and the cells were in good condition; while the combination of copper ions and leucopterin had obvious cell killing effect on normal cells and the cell morphology changed significantly.

[0089] 11) Comparative cytotoxicity experiment of copper-piceatannol nanoparticles and copper ions and piceatannol combination:

[0090] 3T3 were seeded in a 96-well plate and incubated for 24 h. The cell number was measured by a cell counter and reached 8,000 cells per well. Then, copper-piceatannol nanoparticles (50 μg mL -1 ) were incubated with corresponding amounts of copper ions and piceatannol. After 8 hours, MTT was added to detect cytotoxicity and the absorbance at 490 nm was measured.

[0091] Through cytotoxicity experiments ( Fig.15 ) proved that copper-leucopterin nanoparticles have better biosafety than the combination of copper ions and leucopterin.

[0092] 12) Copper-piceatannol biodegradability test:

[0093] The biodegradability of copper-piceatannol was evaluated by simulating the concentration of GSH and H2O2 and the acidic environment in the tumor microenvironment. Fig.16 As shown, under GSH (10 mM), H2O2 (100 μM) or acidic conditions, the coordination structure of copper-piceatannol was destroyed, releasing copper ions and piceatannol.

[0094] Example 2

[0095] The preparation method of copper-piceatannol nanoparticles comprises the following steps: 1) weighing 100 mg of PVP k30 and mixing it with 10 mL of water, and dissolving it by ultrasonication.

[0096] 2) Weigh 70 mg CuCl2·2H2O and mix with 30 mL water and dissolve by ultrasonication.

[0097] 3) Mix the PVP k30 aqueous solution and the CuCl2·2H2O aqueous solution under stirring at 800 rpm and stir for 50 minutes.

[0098] 4) Slowly add 1 mL of piceatannol methanol solution (60 mg / mL) into the solution.

[0099] 5) The solution was then adjusted to a pH of 12 using sodium hydroxide solution.

[0100] 6) After stirring at room temperature for 16 h, a dark brown solid product was obtained by centrifugation at 12000 rpm for 20 min.

[0101] Example 3

[0102] The preparation method of copper-piceatannol nanoparticles comprises the following steps: 1) weighing 50 mg of PVP k30 and mixing it with 10 mL of water, and dissolving it by ultrasonication.

[0103] 2) Weigh 90 mg CuCl2·2H2O and mix with 30 mL water and dissolve by ultrasonication.

[0104] 3) Mix the PVP k30 aqueous solution and the CuCl2·2H2O aqueous solution under stirring at 800 rpm and stir for 80 minutes.

[0105] 4) Slowly add 1 mL of piceatannol methanol solution (60 mg / mL) into the solution.

[0106] 5) The solution was then adjusted to a pH of 13 using sodium hydroxide solution.

[0107] 6) After stirring at room temperature for 8 h, a dark brown solid product was obtained by centrifugation at 12000 rpm for 20 min.

[0108] Comparative Example 1

[0109] The preparation method of copper-piceatannol nanoparticles comprises the following steps: 1) weighing 250 mg of PVP k30 and mixing it with 10 mL of water, and dissolving it by ultrasonication.

[0110] 2) Weigh 42.5 mg CuCl2·2H2O and mix with 30 mL water and dissolve by ultrasonication.

[0111] 3) The PVP k30 aqueous solution and the CuCl2·2H2O aqueous solution were mixed under stirring at 800 rpm and stirred for 60 minutes.

[0112] 4) Slowly add 1 mL of piceatannol methanol solution (60 mg / mL) into the solution.

[0113] 5) The solution was then adjusted to a pH of 12 using sodium hydroxide solution.

[0114] 6) After stirring at room temperature for 12 h, a dark brown solid product was obtained by centrifugation at 12000 rpm for 20 min.

[0115] The copper-piceatannol nanoparticles prepared in Comparative Example 1 were characterized by transmission electron microscopy. From the figure, it can be seen that the prepared nanoparticles are irregular nanoparticles, such as Figure 2 As shown, the product does not meet the requirements.

[0116] Comparative Example 2

[0117] The preparation method of copper-piceatannol nanoparticles comprises the following steps: 1) weighing 250 mg of PVP k30 and mixing it with 10 mL of water, and dissolving it by ultrasonication.

[0118] 2) Weigh 85 mg CuCl2·2H2O and mix with 30 mL water and dissolve by ultrasonication.

[0119] 3) The PVP k30 aqueous solution and the CuCl2·2H2O aqueous solution were mixed under stirring at 800 rpm and stirred for 60 minutes.

[0120] 4) Slowly add 0.5 mL of piceatannol methanol solution (60 mg / mL) into the solution.

[0121] 5) The solution was then adjusted to a pH of 12 using sodium hydroxide solution.

[0122] 6) After stirring at room temperature for 12 h, a dark brown solid product was obtained by centrifugation at 12000 rpm for 20 min.

[0123] The molar ratio of divalent copper ion to piceatannol was changed to 4:1. Fig.14 As shown, the copper-piceatannol nanoparticles prepared in Comparative Example 2 were characterized by transmission electron microscopy. Figure 3 It can be seen that the prepared copper-piceatannol is nanoparticles of uneven length.

[0124] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing copper-piceatannol nanoparticles, Its characteristics are: Polyvinyl pyrrolidone and divalent copper salt are uniformly mixed, and after adding piceatannol, the pH value is adjusted to be not less than 10, and then reacted under stirring conditions, and the obtained nanoparticles are copper-piceatannol nanoparticles.

2. The method for preparing copper-piceatannol nanoparticles according to claim 1, Its characteristics are: The viscosity grade of polyvinyl pyrrolidone is K30 and the molecular weight is 44000-54000.

3. The method for preparing copper-piceatannol nanoparticles according to claim 1, Its characteristics are: The input mass ratio of polyvinyl pyrrolidone to divalent copper salt is 2.5-6:1, preferably 2.9-3.6:1; Alternatively, the molar ratio of the divalent copper salt to piceatannol is 1.50-3.00:1; or 1.50-2.50:1; or 1.50-2.20:

1.

4. The method for preparing copper-piceatannol nanoparticles according to claim 1, Its characteristics are: Adjust pH to 11-13; Alternatively, the reaction time under stirring conditions is 8 to 16 hours.

5. The method for preparing copper-piceatannol nanoparticles according to claim 1, Its characteristics are: After the reaction, centrifugal separation is performed; or, the rotation speed of the centrifugal separation is 11000-13000 rpm, and the centrifugal time is 10-20 min.

6. A copper-piceatannol nanoparticle, Its characteristics are: Obtained by the preparation method according to any one of claims 1 to 5.

7. A pharmaceutical composition, Its characteristics are: The invention comprises the copper-piceatannol nanoparticles according to claim 6, and pharmaceutical excipients.

8. Use of the copper-piceatannol nanoparticles according to claim 6 or the pharmaceutical composition according to claim 7 in the preparation of anti-tumor drugs.

9. The use according to claim 8, Its characteristics are: The anti-tumor drug has any one of the following effects: (1) Catalytic H 2 O 2 Produces oxygen and / or hydroxyl radicals; (2) Oxidation of glutathione to oxidized glutathione; (3) depletion of intracellular polyamines; (4) inducing enhanced cell pyroptosis; and / or, promoting the palmitoylation of GSDMD and GSDMD-N by upregulating the expression of zDHHC5 and zDHHC9, thereby further enhancing cell pyroptosis.

10. The use according to claim 8, Its characteristics are: The tumor is a breast tumor.

Citation Information

Patent Citations

  • Antitumor composition

    CN106309485A

  • Needle-shaped copper-gallic acid nano enzyme as well as preparation method and application thereof

    CN116077527A

  • Preparation method and application of degradable copper-tannic acid-chlorin e6 nano-composite for inducing pyroptosis

    CN117462679A